SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Solana (SOL) is a cryptocurrency launched in 2020. Solana has a current supply of 636,822,022.65079832 with 590,150,211.79771733 in circulation. The last known price of Solana is 94.05303263 USD and is down -1.56 over the last 24 hours. It is currently trading on 1189 active market(s) with $1,556,044,818.54 traded over the last 24 hours. More information can be found at https://solana.com.

Solana

Solana is being discussed amid a broad crypto pullback, with traders citing concerns about a reported major Binance security incident alongside persistent technical weakness. Bearish voices warn of more downside, while others view the dip as a buying opportunity and say they are accumulating or staking SOL.

ExxonMobil Holdings Corp. is an international energy and petrochemical company, which creates solutions that improve quality of life and meets society’s evolving needs. The company is headquartered in Spring, TX.

ExxonMobil Holdings Corp.

Exxon Mobil Corp

Exxons stronger-than-expected Q3 results, led by a surge in refining earnings, and its planned shareholder returns have drawn attention as the stock reached a 52-week high. Traders are debating whether the breakout can continue or the shares look extended after the run-up.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Attention centers on the FDAs pending decision on Capricors deramiocel for Duchenne muscular dystrophy, with traders weighing the amended application and upper-limb data against the earlier negative AdCom and statistical concerns. Bulls read recent launch hiring and a more flexible rare-disease regulatory climate as encouraging signs, while skeptics stress that neither hiring nor community advocacy guarantees approval.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantirs upcoming earnings report is the dominant focus, with traders looking for guidance and growth to clear high expectations rather than relying on a beat alone. The pullback and broader weakness in AI and tech stocks have sharpened the debate: bulls expect strong results to support the premium valuation, while bears warn that even solid results could trigger a selloff if guidance disappoints.

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Gilead Sciences, Inc.

Gileads stronger-than-expected quarterly results, raised product-sales outlook and continued HIV-franchise growth are driving attention as shares reach fresh highs. Traders are broadly positive on the results, while some interpret put-heavy options activity as possible profit-taking or a hedge after the run-up.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TGTXs breakout to fresh 52-week highs is drawing attention ahead of its expected Q3 report, with traders focused on whether BRIUMVIs sales momentum and guidance will support the rally. Buyout and short-squeeze theories are adding to the bullish chatter, but neither is confirmed, and some traders warn that expectations may already be elevated.

XPeng, Inc. is a global physical AI company, which engages in bringing artificial intelligence into the physical world to reshape future mobility and smart living. It developed a full-stack physical AI architecture spanning Turing AI chips, world foundation models, and integrated software and hardware applications. The firm's product portfolio includes smart EVs, robotaxis, and humanoid robots. The company's sales and services drives continuous technological innovation and fosters an open physical AI ecosystem, making life smarter, safer, and better for users worldwide. XPeng, Inc. was founded by Xiao Peng He, Heng Xia, and Tao He in 2015 and is headquartered in Guangzhou, China.

XPeng Inc - ADR

XPengs record October deliveries and sharply higher overseas sales are drawing attention, with traders debating whether the volume growth can translate into better margins and support its Q4 targets. The operational news is met with caution as many point to the stocks prolonged decline, China EV competition and profitability concerns.

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

Inovios FDA accelerated approval of a competing treatment for recurrent respiratory papillomatosis has put pressure on Precigens PAPZIMEOS and sparked debate over how much market share the rival could take. Traders point to Precigens first-mover position, full approval and established commercial launch, while others argue the new treatments different regimen could intensify competition.

Applied Optoelectronics, Inc. engages in the design and manufacture of optical communications products. Its products include optical devices, such as laser diodes, photodiodes, related modules and circuitry, and equipment for applications in fiber-to-the-home, cable television, point to point communications, and wireless. The company was founded by Chih Hsiang Lin on February 28, 1997 and is headquartered in Sugar Land, TX.

Applied Optoelectronics Inc

AAOI is drawing attention amid a sharp pullback alongside other AI and optical-networking stocks, with traders pointing to broader AI-sector selling and concerns about spending, valuation, and further share dilution rather than a confirmed company-specific catalyst. The move has split the community between dip buyers betting on data-center demand and bearish traders worried about continued downside ahead of earnings.

Altria Group, Inc. is a holding company, which engages in the manufacture and sale of cigarettes in the United States. It operates through the following segments: Smokeable Products, Oral Tobacco Products, E-Vapor Products and All Other. The Smokeable Products segment consists of cigarettes manufactured and sold by PM USA, and machine-made large cigars and pipe tobacco manufactured and sold by Middleton. The Oral Tobacco Products segment includes MST products manufactured and sold by USSTC, and oral nicotine pouches manufactured and sold by Helix. The E-Vapor Products segment contracts with third-party importers to supply all of its products and sells its e-vapor products to customers in the United States. The All Other segment refers to the financial results of NJOY, Helix ROW, and the IQOS System heated tobacco business. The company was founded in 1919 and is headquartered in Richmond, VA.

Altria Group Inc.

Altrias third-quarter report beat expectations, lifted its full-year outlook and expanded its buyback, drawing attention as shares approached record highs. Traders welcomed the earnings and shareholder-return news, while some remained cautious about declining cigarette volumes and the sustainability of the rally.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


estill01

ethan stillman